Skin & aging Neurotransmitter-inhibiting peptide
Acetyl hexapeptide-8
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- Also known as
- Argireline
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Acetyl hexapeptide-8, sold in skincare as Argireline, is a synthetic peptide modeled on the nerve protein SNAP-25 and marketed as a topical, "Botox-like" way to soften the appearance of expression lines. In lab and small clinical studies it interferes with the SNARE complex that nerves use to trigger muscle contraction, and a 2013 randomized study found it reduced the appearance of peri-orbital wrinkles over four weeks. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Moderate.
At a glance
- What it is
- Synthetic peptide used in anti-aging skincare, best known by the trade name Argireline
- How it works
- "Neurotransmitter-inhibiting" peptide modeled on the nerve protein SNAP-25, marketed as a topical alternative to Botox for expression lines
- FDA status
- Cosmetic ingredient rather than a drug, so does not require FDA approval
- Evidence strength
- Moderate research
Summary
Acetyl hexapeptide-8, sold as Argireline, is a cosmetic peptide marketed for expression lines. See how it works, what studies show, and its non-drug status.
What is acetyl hexapeptide-8?
Acetyl hexapeptide-8 is a synthetic six-amino acid peptide used as a cosmetic ingredient, best known by the trade name Argireline. It is also called acetyl hexapeptide-3, an older name for the same molecule. Its sequence is patterned on the end of SNAP-25, a protein that nerves use to release the signals that make muscles contract.
It is sold in serums and creams marketed for anti-aging, and it is applied topically to the skin.
How does it work?
Acetyl hexapeptide-8 softens the look of expression lines by reducing the small muscle contractions that create them. Nerves trigger those contractions by releasing a chemical signal, and that release depends on a group of proteins called the SNARE complex, of which SNAP-25 is a part. In laboratory studies, acetyl hexapeptide-8 mimics the end of SNAP-25 and competes with it, which interferes with SNARE complex formation and reduces the release of the signal that tells the muscle to contract. This is the same broad target as Botox, but acetyl hexapeptide-8 is applied topically and is far milder, not an injection that blocks the nerve.
One important limit is delivery. Because it is a relatively large, water-loving peptide, how well it crosses the skin barrier to reach the nerves underneath is debated, and that penetration question is a major reason its effect is modest.
Is it FDA-approved?
Safety note
Status: Cosmetic ingredient rather than a drug, so does not require FDA approval
Category: Cosmetic and topical · Primary body area: Skin & aging
No, and it does not need to be. The FDA does not approve cosmetics or most cosmetic ingredients before they go on the market. Cosmetics are regulated and must be safe when used as directed and properly labeled, but there is no pre-market approval step the way there is for drugs, so no anti-aging peptide in a serum is "FDA-approved."
The line that actually matters for an ingredient like this is the difference between a cosmetic and a drug. A product is a cosmetic when it is intended to improve appearance, but if it claims to change the structure or function of the skin, such as a claim to paralyze muscles, the FDA can regulate it as an unapproved drug. This is why skincare claims are written around the appearance of lines rather than a promised physiological change.
What is it used for?
Acetyl hexapeptide-8 is used almost entirely in topical anti-aging products. It is included to soften the appearance of expression lines and wrinkles, especially forehead lines and the crow's feet around the eyes. It is one of the most common peptide ingredients in over-the-counter skincare.
What does the research show?
Editor’s note
Evidence strength: Moderate research
It has human trial evidence, including a 2013 randomized, placebo-controlled study, but that evidence is limited, since the studies are small, often manufacturer-associated, and complicated by real questions about how well the peptide penetrates the skin.
The main controlled evidence is a 2013 randomized, placebo-controlled study in 60 people, in which a topical argireline product reduced the appearance of peri-orbital wrinkles over four weeks compared with placebo. A 2025 review and other small studies report similar modest improvements, while noting that many studies are small or manufacturer-associated and that skin penetration is a genuine question. The research supports a modest cosmetic benefit, not a result like injectable Botox.
What are the side effects?
Topical acetyl hexapeptide-8 is generally well tolerated, and a cosmetic-industry safety review assessed it as safe as used in cosmetics. As with any skincare ingredient, some people can still experience:
- Mild redness
- Irritation
- An allergic reaction
For that reason, a patch test before regular use is sensible. Because the peptide is applied to the skin rather than injected, its safety considerations are those of a typical cosmetic ingredient.
Sources: the 2013 randomized controlled trial of argireline (Wang et al., American Journal of Clinical Dermatology, DOI: 10.1007/s40257-013-0009-9, indexed on PubMed); a 2025 review of acetyl hexapeptide-8 in cosmeceuticals; the Cosmetic Ingredient Review safety assessment; and FDA guidance on how cosmetics are regulated. This document is educational and does not constitute medical advice or a treatment claim.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
safety review (PDF)
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
Compare every peptide’s status in the peptide regulatory status database
More for Skin & aging
View all skin & aging peptides →- Cosmetic & topical Skin & aging
Acetyl-Octapeptide-3
SNAP-8
Acetyl octapeptide-3, sold in skincare as SNAP-8, is a synthetic eight-amino acid peptide modeled on the nerve protein SNAP-25 and marketed as a stronger successor to Argireline for softening the appearance of expression lines. Like Argireline, it is designed to interfere with the SNARE complex that nerves use to trigger muscle contraction, but its own published human evidence is thin and comes mostly from the manufacturer. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Low.
- Cosmetic & topical Skin & aging
Acetyl-Tetrapeptide-5
Eyeseryl
Acetyl tetrapeptide-5, sold in skincare as Eyeseryl, is a synthetic four-amino acid peptide used in eye creams to soften the look of under-eye bags and puffiness. It is thought to work in two ways, by easing the fluid buildup that makes the under-eye area look swollen and by limiting the glycation that stiffens collagen, though its published evidence comes almost entirely from the manufacturer. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Low.
- FDA-approved Skin & aging
Afamelanotide
Afamelanotide is a synthetic, longer-lasting analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates the MC1R receptor on pigment cells to boost the skin's own protective eumelanin. The FDA approved it in 2019 as Scenesse, a subcutaneous implant for adults with erythropoietic protoporphyria (EPP), a rare light-sensitivity disorder. In the pivotal 2015 placebo-controlled trials, U.S. patients (94) logged a median 69.4 pain-free hours in direct sunlight versus 40.8 on placebo (P = 0.04). EU patients (74) logged 6.0 versus 0.8 hours (P = 0.005).
- FDA-approved Skin & aging
Bacitracin
Bacitracin is a cyclic polypeptide antibiotic produced by Bacillus bacteria that kills gram-positive bacteria by blocking the construction of their cell wall. It is best known as an over-the-counter topical ointment for preventing infection in minor cuts, scrapes, and burns, often combined with neomycin and polymyxin B in "triple antibiotic" products. It is widely available over the counter, but it is also a common cause of allergic skin reactions, and its injectable form was withdrawn over kidney-toxicity concerns.
- Cosmetic & topical Skin & aging
Carnosine
Carnosine is a naturally occurring dipeptide, made of the amino acids beta-alanine and histidine, used in skincare as an antioxidant ingredient. Laboratory and ex-vivo skin studies suggest it can neutralize reactive oxygen species and limit glycation, a process in which sugars stiffen skin proteins, which is the rationale for using it in products aimed at the appearance of aging skin. As of 2026, the evidence for topical carnosine is largely from lab and ex-vivo studies rather than large human appearance trials.
- Cosmetic & topical Skin & aging
Copper-Tripeptide-1
GHK-Cu
Copper tripeptide-1, often called GHK-Cu, is a three-amino acid peptide (glycine-histidine-lysine) bound to a copper ion and used in skincare for its proposed role in skin renewal. Laboratory and animal studies show it can signal cells to make collagen and other matrix components. Independent human evidence is thin. In a randomized trial of 13 patients after CO2 laser resurfacing, GHK-Cu skincare showed no significant difference in redness or skin quality in blinded evaluations, though patients rated their overall skin quality higher (p = 0.04). As of 2026 it is a cosmetic ingredient, not an FDA-approved drug.